AU2011232627B2 - Crystalline forms of a macrolide, and uses therefor - Google Patents

Crystalline forms of a macrolide, and uses therefor Download PDF

Info

Publication number
AU2011232627B2
AU2011232627B2 AU2011232627A AU2011232627A AU2011232627B2 AU 2011232627 B2 AU2011232627 B2 AU 2011232627B2 AU 2011232627 A AU2011232627 A AU 2011232627A AU 2011232627 A AU2011232627 A AU 2011232627A AU 2011232627 B2 AU2011232627 B2 AU 2011232627B2
Authority
AU
Australia
Prior art keywords
cem
ray powder
powder diffraction
compound
diffraction pattern
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2011232627A
Other languages
English (en)
Other versions
AU2011232627A1 (en
Inventor
David E. Pereira
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cempra Pharmaceuticals Inc
Original Assignee
Cempra Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44673574&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2011232627(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cempra Pharmaceuticals Inc filed Critical Cempra Pharmaceuticals Inc
Publication of AU2011232627A1 publication Critical patent/AU2011232627A1/en
Application granted granted Critical
Publication of AU2011232627B2 publication Critical patent/AU2011232627B2/en
Priority to AU2016203986A priority Critical patent/AU2016203986B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2011232627A 2010-03-22 2011-03-22 Crystalline forms of a macrolide, and uses therefor Ceased AU2011232627B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2016203986A AU2016203986B2 (en) 2010-03-22 2016-06-15 Crystalline forms of a macrolide, and uses therefor

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31606310P 2010-03-22 2010-03-22
US61/316,063 2010-03-22
PCT/US2011/029424 WO2011119604A1 (en) 2010-03-22 2011-03-22 Crystalline forms of a macrolide, and uses therefor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2016203986A Division AU2016203986B2 (en) 2010-03-22 2016-06-15 Crystalline forms of a macrolide, and uses therefor

Publications (2)

Publication Number Publication Date
AU2011232627A1 AU2011232627A1 (en) 2012-10-18
AU2011232627B2 true AU2011232627B2 (en) 2016-03-17

Family

ID=44673574

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2011232627A Ceased AU2011232627B2 (en) 2010-03-22 2011-03-22 Crystalline forms of a macrolide, and uses therefor
AU2016203986A Ceased AU2016203986B2 (en) 2010-03-22 2016-06-15 Crystalline forms of a macrolide, and uses therefor

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2016203986A Ceased AU2016203986B2 (en) 2010-03-22 2016-06-15 Crystalline forms of a macrolide, and uses therefor

Country Status (19)

Country Link
US (4) US8975386B2 (enExample)
EP (2) EP2550286B1 (enExample)
JP (4) JP5711352B2 (enExample)
KR (2) KR102006200B1 (enExample)
CN (2) CN103080122A (enExample)
AU (2) AU2011232627B2 (enExample)
BR (1) BR112012023950A2 (enExample)
CA (1) CA2793884C (enExample)
DK (1) DK2550286T3 (enExample)
ES (1) ES2564097T3 (enExample)
HR (1) HRP20160168T1 (enExample)
IL (1) IL222018B (enExample)
MX (1) MX361413B (enExample)
MY (1) MY162411A (enExample)
NZ (1) NZ602544A (enExample)
PL (1) PL2550286T3 (enExample)
RU (1) RU2650883C2 (enExample)
SI (1) SI2550286T1 (enExample)
WO (1) WO2011119604A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3738591A3 (en) 2003-03-10 2021-03-24 Merck Sharp & Dohme Corp. Novel antibacterial agents
AU2008316830B2 (en) 2007-10-25 2016-03-17 Cempra Pharmaceuticals, Inc. Process for the preparation of macrolide antibacterial agents
US9072759B2 (en) 2008-10-24 2015-07-07 Cempra Pharmaceuticals, Inc. Biodefenses using triazole-containing macrolides
US9937194B1 (en) 2009-06-12 2018-04-10 Cempra Pharmaceuticals, Inc. Compounds and methods for treating inflammatory diseases
ES2608285T3 (es) 2009-09-10 2017-04-07 Cempra Pharmaceuticals, Inc. Procedimientos para el tratamiento de paludismo, tuberculosis y enfermedades por MAC
ES2564097T3 (es) * 2010-03-22 2016-03-17 Cempra Pharmaceuticals, Inc. Formas cristalinas de un macrólido, y usos de las mismas
ES2636948T3 (es) 2010-05-20 2017-10-10 Cempra Pharmaceuticals, Inc. Procesos para preparar macrólidos y cetólidos e intermediarios para los mismos
WO2012034058A1 (en) 2010-09-10 2012-03-15 Cempra Pharmaceuticals, Inc. Hydrogen bond forming fluoro ketolides for treating diseases
IN2014DN08939A (enExample) 2012-03-27 2015-05-22 Cempra Pharmaceuticals Inc
CN105163785A (zh) 2013-03-14 2015-12-16 森普拉制药公司 用于治疗呼吸道疾病的方法及其制剂
RU2015138797A (ru) 2013-03-15 2017-04-24 Семпра Фармасьютикалс, Инк. Конвергентные способы получения макролидных антибактериальных агентов
MX377459B (es) 2013-04-04 2025-03-10 Harvard College Macrolidos y metodos para su preparacion y uso.
CA2957034A1 (en) * 2014-08-05 2016-02-11 Cempra Pharmaceuticals, Inc. Powder oral suspension formulations of antibacterial agents
CN104151382B (zh) * 2014-08-08 2016-09-14 广东东阳光药业有限公司 一种固态大环内酯的晶型
CN104311611B (zh) * 2014-08-13 2017-01-18 广东东阳光药业有限公司 一种制备固态大环内酯的方法
WO2016057798A1 (en) 2014-10-08 2016-04-14 President And Fellows Of Harvard College 14-membered ketolides and methods of their preparation and use
CN107530365A (zh) 2015-03-25 2018-01-02 哈佛大学的校长及成员们 具有修饰的脱氧糖胺糖的大环内酯及其用途
WO2017061431A1 (ja) * 2015-10-05 2017-04-13 富山化学工業株式会社 ソリスロマイシンを含む錠剤
EP3190122A1 (en) * 2016-01-08 2017-07-12 LEK Pharmaceuticals d.d. A novel synthetic pathway towards solithromycin and purification thereof
WO2018045294A1 (en) * 2016-09-02 2018-03-08 Cempra Pharmaceuticals, Inc. Processes for preparing fluoroketolides
AU2020395150A1 (en) * 2019-12-02 2022-06-23 AliquantumRx, Inc. Salts and polymorphs of cethromycin for the treatment of disease salts and polymorphs of cethromycin

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331803A (en) 1980-06-04 1982-05-25 Taisho Pharmaceutical Co., Ltd. Novel erythromycin compounds
US4474768A (en) 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
US4742049A (en) 1986-06-04 1988-05-03 Abbott Laboratories Semisynthetic erythromycin antibiotics
IL114589A (en) 1990-11-21 1999-12-22 Roussel Uclaf Intermediates for the preparation of erythromycin derivatives
US5985844A (en) 1992-03-26 1999-11-16 Merck & Co., Inc. Homoerythromycin A derivatives modified at the 4"-and 8A-positions
US5527780A (en) 1992-11-05 1996-06-18 Roussel Uclaf Erythromycin derivatives
FR2697524B1 (fr) 1992-11-05 1994-12-23 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
FR2718450B1 (fr) 1994-04-08 1997-01-10 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
FR2719587B1 (fr) 1994-05-03 1996-07-12 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
US5834428A (en) 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
FR2739620B1 (fr) 1995-10-09 1997-12-19 Roussel Uclaf Nouveaux derives de la 5-0-desosaminyl 6-o-methyl erythronolide a, leur procede de preparation et leur application a la preparation de produits biologiquement actifs
US6274715B1 (en) 1995-11-08 2001-08-14 Abbott Laboratories Tricyclic erythromycin derivatives
FR2742757B1 (fr) 1995-12-22 1998-01-30 Roussel Uclaf Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
FR2745290B1 (fr) 1996-02-28 1998-04-03 Roussel Uclaf Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
DE69733723T2 (de) 1996-09-04 2006-04-20 Abbott Laboratories, Abbott Park 6-o-Substituierte Ketoliden mit antibakteriellen Wirkung
US6407074B1 (en) 1997-06-11 2002-06-18 Pfizer Inc C-4″-substituted macrolide derivatives
HN1998000086A (es) 1997-06-11 1999-03-08 Pfizer Prod Inc Derivados de 9 - desofo - 9 aza - 9a - homoeritromicina a - c - 4 sustituidos.
TR199902995T2 (xx) 1997-06-11 2000-02-21 Pfizer Products Inc. 9-Oksim eritromisin t�revleri
HN1998000159A (es) 1997-10-29 1999-02-09 Monsanto Co Derivados de 9- amino - 3 ceto eritromicina
IL135792A0 (en) 1997-12-01 2001-05-20 Abbott Lab 6-o-alkyl derivatives of erythronolide b
FR2777282B1 (fr) 1998-04-08 2001-04-20 Hoechst Marion Roussel Inc Nouveaux derives de la 2-fluoro 3-de((2,6-dideoxy 3-c-methyl 3-0-methyl-alpha-l-ribohexopyranosyl) oxyl) 6-o-methyl 3-oxo erythromycine, leur procede de preparation et leur application a la synthese de principes actifs de medicaments
US6020521A (en) 1998-08-26 2000-02-01 Abbott Laboratories Macrolide LHRH antagonists
US6387885B1 (en) 1998-08-26 2002-05-14 Abbott Laboratories 3′,3′-N-bis-desmethyl-3′-N-cycloalkyl erythromycin derivatives as LHRH antagonists
FR2785612A1 (fr) 1998-11-10 2000-05-12 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
KR100317907B1 (ko) * 1998-11-24 2001-12-24 김 완 주 신규한 중간체, 이를 이용한 마크로라이드계 항생제의제조방법
FR2786188B1 (fr) 1998-11-24 2002-10-31 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur applicaion comme medicaments
WO2000034297A1 (en) 1998-12-10 2000-06-15 Pfizer Products Inc. Carbamate and carbazate ketolide antibiotics
ID30233A (id) 1999-01-27 2001-11-15 Pfizer Prod Inc Antibiotika ketolida
CA2411293A1 (en) 1999-01-28 2000-07-28 Pfizer Products Inc. Novel azalides and methods of making same
US6399582B1 (en) 1999-04-16 2002-06-04 Ortho-Mcneil Pharmaceutical, Inc. Ketolide antibacterials
KR20020007374A (ko) 1999-04-16 2002-01-26 추후제출 매크롤라이드 항감염제
US6420535B1 (en) 1999-06-07 2002-07-16 Abbott Laboratories 6-O-carbamate ketolide derivatives
US6437106B1 (en) 1999-06-24 2002-08-20 Abbott Laboratories Process for preparing 6-o-substituted erythromycin derivatives
WO2001010878A1 (fr) 1999-08-06 2001-02-15 Taisho Pharmaceutical Co., Ltd. Derives d'erythromycine a
KR100336447B1 (ko) 1999-11-24 2002-05-15 민경윤 클라리스로마이신의 개선된 제조방법
JP2001261694A (ja) 2000-03-06 2001-09-26 Pfizer Prod Inc ケトライド抗生物質
ES2242668T3 (es) 2000-03-15 2005-11-16 Hanmi Pharm. Co., Ltd. Metodo para obtener claritromicina en cristales de forma ii.
US20020115621A1 (en) 2000-08-07 2002-08-22 Wei-Gu Su Macrolide antibiotics
GB0031312D0 (en) 2000-12-21 2001-02-07 Glaxo Group Ltd Macrolides
EP1320355B1 (en) 2001-05-18 2006-04-05 Chiron Corporation System for delivering a tobramycin formulation
EP1404693A2 (en) 2001-07-03 2004-04-07 Chiron Corporation C12 modified erythromycin macrolides and ketolides having antibacterial activity
US20030176327A1 (en) 2001-10-25 2003-09-18 Cassell Gail Houston Antibiotics for treating biohazardous bacterial agents
WO2003072141A1 (en) 2002-02-22 2003-09-04 Pharmacia Corporation Ophthalmic antibiotic drug formulations containing a cyclodextrin compound and cetyl pyridinium chloride
WO2003101972A1 (en) 2002-05-30 2003-12-11 The Scripps Research Institute Copper-catalysed ligation of azides and acetylenes
TW200420573A (en) 2002-09-26 2004-10-16 Rib X Pharmaceuticals Inc Bifunctional heterocyclic compounds and methods of making and using same
ITMI20022292A1 (it) 2002-10-29 2004-04-30 Zambon Spa 9a-azalidi ad attivita' antiinfiammatoria.
EP3738591A3 (en) * 2003-03-10 2021-03-24 Merck Sharp & Dohme Corp. Novel antibacterial agents
EP1618120A2 (en) 2003-04-25 2006-01-25 Chiron Corporation Novel ketolide derivatives
US20050014706A1 (en) 2003-07-14 2005-01-20 Kanakeshwari Falzari Method of treating tuberculosis
US7457520B2 (en) 2003-07-24 2008-11-25 Time Warner Cable, Inc. Technique for providing a virtual digital video recorder service through a communications network
US20060116336A1 (en) 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
AU2005238313A1 (en) 2004-04-28 2005-11-10 Alembic Limited Process for the preparation of telithromycin
JP2008508322A (ja) 2004-07-28 2008-03-21 ランバクシー ラボラトリーズ リミテッド 抗菌剤としてのケトライド誘導体
PL1836211T3 (pl) * 2004-12-21 2010-07-30 Pfizer Prod Inc Makrolidy
ATE477805T1 (de) 2005-01-14 2010-09-15 Glaxosmithkline Zagreb 9a-carbamoyl-y-aminopropyl- und 9a-thiocarbamoyl- y-aminopropyl-azalide mit antimalaria-aktivität
WO2007039914A2 (en) 2005-10-06 2007-04-12 Alembic Limited Novel polymorphs of telithromycin
WO2007059307A2 (en) * 2005-11-15 2007-05-24 Teva Pharmaceutical Industries Ltd. Crystalline and amorphous forms of telithromycin
US20090075916A1 (en) 2005-11-23 2009-03-19 Upadhyay Dilip J Use of Macrolide Derivatives for Treating Acne
DOP2006000268A (es) 2005-12-22 2007-07-31 Pfizer Prod Inc Agentes antibacterianos
CN101129383B (zh) 2006-08-25 2014-04-02 天津和美生物技术有限公司 含氨基糖苷类抗生素的抗生素复方
US7742562B2 (en) * 2007-06-27 2010-06-22 Accuray Incorporated Lower-torso assembly of a treatment couch useable in an X-ray environment
AU2008316830B2 (en) * 2007-10-25 2016-03-17 Cempra Pharmaceuticals, Inc. Process for the preparation of macrolide antibacterial agents
US20110040078A1 (en) 2007-10-25 2011-02-17 Siegfried Wolf Process for the production of telithromycin
US9072759B2 (en) * 2008-10-24 2015-07-07 Cempra Pharmaceuticals, Inc. Biodefenses using triazole-containing macrolides
PL2544537T3 (pl) 2010-03-10 2017-10-31 Cempra Pharmaceuticals Inc Pozajelitowe preparaty antybiotyków makrolidowych
ES2564097T3 (es) * 2010-03-22 2016-03-17 Cempra Pharmaceuticals, Inc. Formas cristalinas de un macrólido, y usos de las mismas

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Raoul J.M. et al, Biochemical Pharmacology, 2007, 74, 639-646 *

Also Published As

Publication number Publication date
IL222018B (en) 2019-05-30
RU2650883C2 (ru) 2018-04-18
EP3009442A1 (en) 2016-04-20
MX361413B (es) 2018-12-05
JP6121387B2 (ja) 2017-04-26
PL2550286T3 (pl) 2016-07-29
EP2550286B1 (en) 2015-12-09
AU2011232627A1 (en) 2012-10-18
US8975386B2 (en) 2015-03-10
DK2550286T3 (en) 2016-02-29
US8759500B2 (en) 2014-06-24
AU2016203986B2 (en) 2016-10-06
US20130018008A1 (en) 2013-01-17
MY162411A (en) 2017-06-15
RU2012144614A (ru) 2014-04-27
EP3009442B1 (en) 2019-06-19
HK1177937A1 (en) 2013-08-30
EP2550286A4 (en) 2013-10-02
KR20130056226A (ko) 2013-05-29
JP2013522367A (ja) 2013-06-13
US20190040096A1 (en) 2019-02-07
MX2012010895A (es) 2013-02-15
US20160244472A1 (en) 2016-08-25
CN108570083A (zh) 2018-09-25
EP2550286A1 (en) 2013-01-30
JP5711352B2 (ja) 2015-04-30
AU2016203986A1 (en) 2016-06-30
CA2793884C (en) 2019-09-10
KR20180101643A (ko) 2018-09-12
CA2793884A1 (en) 2011-09-29
ES2564097T3 (es) 2016-03-17
BR112012023950A2 (pt) 2016-07-05
CN103080122A (zh) 2013-05-01
US20130252915A1 (en) 2013-09-26
JP2017081953A (ja) 2017-05-18
WO2011119604A1 (en) 2011-09-29
JP2015063536A (ja) 2015-04-09
HRP20160168T1 (hr) 2016-03-25
NZ602544A (en) 2014-11-28
KR102006200B1 (ko) 2019-08-01
JP2020002168A (ja) 2020-01-09
SI2550286T1 (sl) 2016-04-29

Similar Documents

Publication Publication Date Title
AU2011232627B2 (en) Crystalline forms of a macrolide, and uses therefor
CA3059777C (en) Crystalline forms of (s)-2-ethylbutyl 2-(((s)-(((2r,3s,4r,5r)-5-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
MX2014005362A (es) Forma iv del clorhidrato de ivabradina.
US20140079783A1 (en) Pharmaceutical Compositions Comprising Rifaximin and Amino acids, Preparation Methods and Use Thereof
JP2013184902A (ja) リファキシミン含有結晶
HK1221229B (en) Crystalline forms of a macrolide, and uses therefor
HK1221229A1 (en) Crystalline forms of a macrolide, and uses therefor
HK1177937B (en) Crystalline forms of a macrolide, and uses therefor
HK1182115A (en) Crystalline forms of a macrolide, and uses therefor
CN108997186B (zh) 反式-4-苯基-5-邻氯苄基吡咯烷酮-2的晶型
CN107474057B (zh) (5-(2-腈基苄基)-4,5,6,7-四氢噻吩并[3,2-c]吡啶-2-基)乙酸酯盐酸盐的晶型及其制备方法和用途
CN113072583A (zh) 一种替诺福韦艾拉酚胺半富马酸盐的结晶及其制备方法
CN112047990B (zh) 阿糖胞苷前药mb07133晶型及其应用
CN113398125B (zh) 替唑尼特药物组合物及其医药用途
CN111320589A (zh) 一种非布司他钠盐a晶型及其制备方法和用途
CN115385931A (zh) 多替拉韦钠的多晶型物及其制备方法
HK40036995A (en) Crystals of glycyrrhizic acid derivatives, crystalline compositions, pharmaceutical compositions and uses thereof
HK40016048A (en) Novel crystalline forms

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired